World tasked

Following the parturition of a premature baby in a Melbourne hospital tardy last year with a rare form of tuberculosis (TB), blood tests are being carried out on 25 babies who were also in the hospital at the quickly of his birth.

The Infection Control Co-ordinator, for Southern Health, Dr. Rhonda Stuart, says the baby contracted the disease from his mother while in her womb; she was unaware she was carrying the bacteria.

Although the mother was healthy experts suspect the TB was present in her pelvis and was passed onto the baby just before or during birth.

The Monash Medical Centre where the baby was born say 25 newborn babies, their parents and 100 staff at the Monash Medical Centre are now being screened for TB as they may have come into contact with the baby.

According to the Monash Medical Centre the mother poses no risk to the community but she remains in hospital, while the baby has been placed in isolation.

Dr. Stuart says even though they believe the risk of anyone acquiring TB from the baby is very small, the precautionary TB screening and testing measures are being offered to people who had prolonged contact with the baby.

Dr. Stuart says congenital tuberculosis is a very rare occurrence especially in Australia and there have only been about 300 cases ever documented.

She says there are probably more cases in developing countries.

The lungs are usually the prime target of the TB germ and the disease is generally passed on through coughs and sneezes; left untreated it can be fatal.

It can remain dormant in a carrier and can be passed on during childbirth or in the womb and those infected with active TB are contagious for a period of around two weeks.

The infection is commonly treated with an extensive course of drugs.

There have been 9 cases of TB reported to Victorian health authorities this month.

A prize rise for poultry is being called for by the NFU (National Farmers’ Union) to help farmers facing losses appropriate to rising energy costs.

In a check into, British Chicken - What Penalty? the NFU warns the poultry industry is in a fragile circumstances. It says an industry price inflation is the only in the way of to secure UK production of subcontract-assured chicken for consumers.

The British chicken industry is currently worth £1.3 billion per year and is the strongest in Europe. The Avian Influenza critical time had little crash on UK chicken sales and our market was skilled to absorb low-cost European chow surpluses. But this has meant added pressure against UK farmers by causing downward pressure on poultry prices.

The NFU is calling on retailers to certify a impartial poultry price to empower farmers to meet consumer claim for British chicken, while achieving a margin over building to invest in the industry’s future.

In addition poultry farmers are skin further production costs to endure growing environmental legislation. The Corruption Prevention and Repress Regulations want to put a stop to and be in control of emissions to air, solid ground and water, and to address vim skill, the consumption of raw materials, commotion and site restoration. Notwithstanding how it will add here £6,000 extra costs to every poultry farm with 40,000 poultry places or more.

NFU poultry board chairman Charles Bourns said: “A price rise is critical so farmers can maintain this affluent, vibrant industry. It has grown year on year in line with consumer popular.”

1. The British Chicken - What Reward? boom is being launched at the Pig and Poultry Fair, being held at the National Agricultural Centre, Warwickshire, on May 9-10, 11am, to which the newswomen is invited to attend.

2. An example of exertion losses at grassroots: A contrivance-sized poultry farmer rearing 200,000 birds at 400,000 kg, could face a loss of 6.2p per kg. This equates to a loss of verging on £25,000 per gang every year. A chicken farmer typically rears about six flocks per year.

3. Chicken equates about one third of total meat production in the UK - six per cent is free range and three per cent is organic - with both markets on the increase.

4. A new-look Poultry Forum magazine championing NFU members is being launched at the fair, with copies handy from the NFU posture, converse Kelly’s Turkeys, in the centre of the main poultry parade. A taster copy will also be available online at http://www.nfuonline.com from May 8.

Scientists studying biological systems at the molecular stage straight now have a new hybrid technique to probe the dynamics of the Holliday junction.

The Holliday junction is a four-stranded DNA structure that forms during a process known as homologous recombination, which occurs when damaged DNA is repaired. Understanding how DNA repairs itself is an essential step in ultimately developing therapies for genetic disorders.

The hybrid technique is described by principal investigator Taekjip Ha and his colleagues at the University of Illinois in the Oct. 12 issue of Science. The Holliday junction is named after geneticist Robin Holliday, who proposed the model of DNA-strand exchange in 1964. To better understand the mechanisms and functions of proteins that interact with the Holliday junction, the researchers needed a way to study the structural and dynamic properties of the junction itself.

“Based on our previous studies, we knew the Holliday junction fluctuated between two structures, but how it moved from one place to the other and what intermediates were visited along the pathway were unknown,” Ha said. With this latest work, the researchers have determined that the intermediate structure is similar to that of a Holliday junction bound to its own processing enzyme.

The hybrid technique combines the exquisite force control of an optical trap and the precise measurement capabilities of single-molecule fluorescence resonance energy transfer. To use the technique, researchers first attach two dye molecules–one green and one red–to the molecule they want to study. Next, they excite the green dye with a laser. Some of the energy moves from the green dye to the red dye, depending upon the distance between them. The changing ratio of the two intensities indicates the relative movement of the two dyes. Therefore, by monitoring the brightness of the two dyes, the researchers can determine the motion of the molecule. With the optical trap, a focused laser beam locks onto a microsphere attached to one end of the molecule to be studied. The optical trap can then pull on the molecule like a pair of tweezers.

The project is funded by the Physics and Molecular and Cellular Biosciences divisions at the National Science Foundation (NSF) through a CAREER award for the development and utilization of advanced single-molecule techniques to study the fundamentals of DNA-protein interactions.

Past techniques, such as X-ray crystallography and nuclear magnetic resonance, have provided a vast amount of structural detail for biological molecules, but the data is largely limited to a static view. Single molecule approaches make it possible to study dynamic interactions at the single molecule level. The ability to follow bioprocesses as they actually occur in real time transforms the way we visualize and ultimately understand the complex dynamics of living systems.

“The two NSF divisions supporting this project have been working closely together for several years to foster this research and other similar approaches,” said NSF Program Manager Denise Caldwell. “These results highlight the importance of fostering a cross-disciplinary approach to understanding complex living systems because input from both directions is essential to the success of the project.” She added that “a lot of junior scientists are migrating into fields like this one because the science is intellectually exciting.”

http://www.nsf.gov/

The National Establish for Health and Clinical Excellence (NICE) has published a further two new commissioning guides to help the NHS in England effectively commission evidence-based care because patients. The guides bed linen the following services:

- Faecal incontinence
- Cognitive Behavioural Therapy for common mental health problems

Each commissioning guide signposts and provides topic-special to bumf on essential clinical and service-interrelated issues to consideration during the commissioning process. They also tender an indicative benchmark of activity to avoid commissioners determine the sincere of maintenance needed locally. Within each commissioning guide, an interactive tool provides data for local contrasting against the benchmark and resources to estimate and inform the expense of commissioning intentions. The Institute aims to yield up to 10 commissioning guides a year. These will be updated annually, with new releases timed to maintain maximum impact on the annual commissioning get ready.

Since January, NICE has published eight commissioning guides and updated commissioning tools published in 2007. Both the updated and new commissioning tools offer enhanced functionality to annihilate users. They under allow commissioners in Strategic Health Authorities (SHA) to log in and contemplation information at Prepare Care Trust (PCT) level. GP practices within a commissioning group/cluster can also give other practices in their cluster permission to cityscape their data and to model commissioning intentions to go to the group.

Dr Dinah Roy, Locality Clinical Starring role and Chair, Sedgefield Practice Based Commissioning Group, County Durham PCT, and NHS Confederation representative said: “In one get ahead I can at present find a suggestion to every dimension I should capture when commissioning a service - theoretical background message and practical information on how to pull the work together. Developing commissioning pathways is mere time-consuming, but thanks to these guides, the process is now far more effectual. Previously, to agree with data on my local population, for example referral patterns, I would need to expect local practices or the PCT. The commissioning guides provide the latest Dr Forward statistics on my section, and also tell me at the beginning of the handle what information I need to go away and find - so in this technique they categorically give me a ‘head start’.”

Jon Tuppen, General Medical Practitioner with Certain Significance, South West Essex PCT said: “The increasing set of commissioning tools being offered by NICE are extremely useful to substantiate commissioning at PCT and PBC level. The coupling to evidence, templates that automatically collect local information, but can also be locally changed, and the unswerving format between subjects provides a noble tool to benefit local verdict making. Earlier I would hold to put commissioning model work on hold on account of three months whilst I gathered together important data. As the indicator data is available within the commissioning guides, it means I can now focus my time on working with providers to take in foolproof we are delivering a safe and effective service to patients.”

To access the guides go to here.

PLEASANT is the independent organisation responsible for providing national conduct on the hoop-la of good health and the prevention and treatment of in no way health.

National Institute for Health and Clinical Excellence (NICE)

Researchers at the University of Utah are enrolling people in a new clinical try-out that uses a patient’s own stem cells to treat ischemic and non-ischemic heart failure.

The solitary-year Cardiac Repair Chamber Treatment of Patients with Dilated Cardiomyopathy (IMPACT-DCM) study intention look at the safeness of injecting Cardiac Repair Cells (CRC) and their ability to correct heart gala.

Patients enrolled in IMPACT-DCM will have their own bone marrow cells pinched (about 3 tablespoons worth), which will then be grown in a culture to distend the number of cells that will help the heart muscle and improve blood flow. Two weeks later, the patient’s stem cells will be injected straight away into the left ventricle of the heart during a minimally invasive surgery developed by Amit N. Patel, M.D., chauvinistic principal investigator by reason of the IMPACT-DCM side and vice-president of cardiovascular regenerative medicine at the University of Utah Style of Pharmaceutical.

“Heart fizzle affects about 5 million Americans, with more than half a million renewed cases diagnosed each year. A subset of these patients has dilated cardiomyopathy (DCM), a condition that leaves the heart weakened, enlarged and powerless to pump blood efficiently. For most of these patients, the no greater than option has been a heart move,” said David A. Bull, M.D., professor and division chief of Cardiothoracic Surgery in the U’s medical school and site principal investigator inasmuch as the enquiry.

“This is the first trial of its kidney in the United States, providing patients who have limited to no other options with a feelings treatment,” said Patel, professor of surgery. “By using a patient’s own cells, we polish off the firm of denial and the requirement for the benefit of potentially venomous immunosuppressive drugs. We count these cells will help with budding blood vessels and support the heart muscle in categorization to improve the heart’s function, thereby greatly improving the patient’s attribute of dash.”

Patients who have been diagnosed with congestive heart failing (NYHA Rank 3 or 4) and are between the ages of 18 and 86 may be eligible to participate in the annoyance. The University of Utah is people of five nationwide sites conducting the BUMPING-DCM analyse, sponsored by Aastrom Biosciences, Inc., a company specializing in autologous apartment products. IMPACT-DCM is a randomized, controlled, Phase II look that will enroll 40 patients nationwide: 20 patients with ischemic DCM and 20 patients with nonischemic DCM.

—————————-
Article adapted by Medical News Today from original press releasing.
—————————-

Source: Chantelle Turner

University of Utah Health Sciences

Researchers in the Communal States say smokers who fall flat to released from smoking by using pills, should not be disheartened and should try again.

Researcher David Gonzales, director of the smoking cessation center at Oregon Health & Science University, says even if the drugs do not work initially smokers should keep trying.

Gonzales says it may take several weeks for many people to fully wean themselves off tobacco and they should not be discouraged when total abstinence is not achieved in the first weeks of treatment with smoking cessation medications.

Gonzales and colleagues have been examining how well the drugs Chantix or Zyban work, and published a study on the topic last year.

In order to see if it took some people longer to quit than others when they used the drugs, the researchers analyzed the results of both studies.

Both Chantix and Zyban can help smokers quit and are licensed for that use; Zyban is an antidepressant and Chantix is designed to block nicotine in the brain.

Gonzales and his colleagues evaluated Chantix versus Zyban in more than 1,000 smokers from June 2003 to April 2005 and found Chantix worked better to help people quit.

At the time, what happened if people kept trying, was not considered.

Gonzales says when the medication does not succeed in making smokers quit within two weeks from the end of the their target quit date, doctors usually tell their patients to discontinue their medication and consider the attempt a failure.

The researchers found that 24 percent of those taking Chantix were able to quit right away, as against 18 percent taking Zyban and just 10 percent given a placebo.

But it was also found that another 20 percent of those taking Chantix and 11 percent taking Zyban were able to quit if they kept trying for up to three months.

Many experts regard tobacco to be as addictive as heroin and cocaine, and people need many attempts to quit.

Gonzales presented his work at a meeting of the Society for Research on Nicotine and Tobacco in Austin, Texas.

Many molecules are enantiomers: they arrange mirror- form versions that may have identical parts but are fair-minded as different as your left-hand hand is from your to be honest. The value of a hypnotic, nonetheless, could depend on whether it is a lefty or a righty, so researchers at the University of Pennsylvania are creating catalysts that will force stupefy molecules to choose sides.

Today, at the American Chemical Society 228th National Meeting, Penn chemist Marisa C. Kozlowski details the methods her lab is using to create the next generation of single-enantiomer catalysts.

“Enantiomers can pose a problem in pharmaceutical research, since the mirror-image of a particular molecule may be harmful or, at the least, useless,” said Kozlowski, an associate professor in Penn Department of Chemistry. “Thalidomide is one famous example. The drug was created was as a mixture of both enantiomers, but researchers at the time did not know the left-handed version caused severe birth defects.”

Not all effects of enantiomers are bad, of course. Spearmint takes its flavor from the right-handed version of a molecule called carvone, while its left-handed enantiomer creates the taste of caraway oil. Recently, however, the potential of harmful enantiomers has come to the attention of the Food and Drug Administration, which promotes the development of single-enantiomer drugs. (See the 1992 policy statement at the FDA Web site.) This has created a pressing need for pharmaceutical companies to develop single-enantiomer drugs.

Unfortunately, the chemistry of creating mixtures of enantiomers is much better known than that for creating batches of single-enantiomer drugs. It was only in 2001 that researchers were awarded a Nobel Prize for the first artificial single-enantiomer catalysts.

Kozlowski and her colleagues are laying the groundwork for the next generation of such catalysts, using techniques that combine empirical observation and computational tools.

In her presentation, Kozlowski will provide an overview of her lab efforts, culminating in the synthesis of natural products, such as nigerone and cercosporin, as well as pharmaceutical agents, such as a Wyeth opiate antagonist.

http://www.upenn.edu

The New York Times on Wednesday examined the capacity “trouble ahead” for managed care companies as “further declines in manufacturing jobs and a dirty economic recovery have planned braked increases in enrollment.” After reaching 52-week highs early this month, share prices of WellPoint, UnitedHealth Group and Cigna since April 7 have “led the way down,” the Times reports. Definitive & Poor’s index of managed care stocks decreased by 8.4% since April 7, compared with a curtailment of 3.3% for the broader S&P-500 index. Investors will be “paying buddy-buddy attention” Wednesday and Thursday when WellPoint and Aetna report enrollment information for the first quarter as part of their financial results, and it is “hard to predict” whether “this tide will soon turn,” according to the Times.

Analyst Comments
Smith Barney analyst Charles Boorady said that the decline in share prices for managed care companies could be attributed in part to investors’ move to pharmaceutical stock, adding that he expects managed care companies to have strong earnings growth between 2006 and 2008 after the Medicare prescription drug benefit goes into effect. However, Sheryl Skolnick, an analyst at Fulcrum Global Partners, said the drug benefit still represents “a great unknown opportunity.” She said that participating companies expect the benefit to provide a new source of profit but added that “until the bids are formulated and awarded, nobody knows how much to expect.” Goldman Sachs analyst Matthew Borsch said, “There are danger signs out there,” adding that Medicare will be only “an incremental positive” for most companies and “doesn’t transform the earnings picture.” Borsch said that not-for-profit Blue Cross and Blue Shield health plans, which have considerable financial reserves, could reduce premiums, a move that could push competitors to follow suit. Joseph France, an analyst at Banc of America Securities, said, “The business is going to get more difficult after five years of expanding margins,” adding, “We think 2006 will be tough” (Freudenheim, New York Times, 4/27).

New York Times

“Reprinted with permission from kaisernetwork.org kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

UroToday.com - Botulinum toxin (BTX) is used therapeutically seeing that various disorders associated with disproportionate powerful contractions including central dystonias. Recently BTX has been successfully used for the treatment of disorders of the gastrointestinal and urinary tracts. Nevertheless, controversy exists with respect to refuge of this treatment.
Respective studies reported autonomic effects of BTX, particularly of BTX B used to reception of cervical dystonia, including dry speak, blurred vision, lightheadedness and constipation.(1,2,3)

In the present boning up intraprostatic injection of BTX A has been successfully used to abridge voiding dysfunction in 77 patients with Non-virulent Prostatic Hyperplasia (BPH).

In another clinical experience, seven patients, all of whom reported no symptomatic improvement with BTX A treatment, have been treated using intraprostatic injection of BTX B (NeuroBloc, Elan, Ireland) with the for all that technique, in order to avoid the risk of resistance to BTX A and to obtain long-lasting results. The NeuroBloc equivalent was determined by multiplying by 50 the dose as Botox units, so 10000 U of BTX B were used.

Two months after injections, AUA score decreased from 23.6 ±1.7 to 12.3 ±2 points (P =0.00001), serum PSA from 4.1 ±0.6 to 2.0 ±0.8 ng per ml (P =0.0004), prostatic quantity from 47.8 ±9.8 to 26.1 ±6.0 ml (P =0.0009), and residuary volume from 76 ±26 to 47 ±7.6 ml (P =0.02). At the done on the dot, middling tip urinary flow grade increased from 9.4 ±3.0 to 14.4 ±0.7 ml per second (P =0.002). Two of the seven patients (40%) professional erectile dysfunction and unembellished mouth.

Furthermore, to enquire cardiovascular autonomic effects of BTX A, we possess studied six patients, from 22 to 62 years old, without detectable cardiovascular or autonomic diseases, treated with 150 units (0.75 ml) of BTX A (Dysport, Ipsen SpA, Milan, Italy) in place of lingering anal fissure. We have utilized the Ewing usage at baseline (before treatment) and repeated the tests within 96 hours and within 30 days after treatment with BTX. The Ewing treaty, including calculation of heart rate changes during deep breathing, Valsalva maneuver and duration up; blood-pressure measurement during handgrip and during standing up, make been developed to assess the autonomic control of cardiovascular technique and to distinguish autonomic neuropathy. To class the rigidity of damage of ANS, a score (0 = normal response; 1 = borderline; 2 = abnormal) is given to each trial. The final get laid can change from 0/10-1/10 (normal pattern), to 2/10-4/10 (borderline pattern), to 5/10-10/10 (abnormal pattern). No person of the patients had worsening of test scores after toxin injections. In specifically, before treatment a borderline pattern (2/10 score) was set in 4 patients. At 96-hour ranking, a borderline pattern (2/10 score) was rest in 1 patient. At 30 days evaluation, all patients who had previously reported strange vocal score no longer had such scores, and a normal pattern (0/10) was found in all treated patients.

In these clinical trials BTX did not bring up any pensive cardiovascular adverse events. Besides, BTX B caused significant reduction of saliva movie and erectile dysfunction in 40% of patients. According to our results, in a recent duplicated blind randomized trial BTX A and B were compared in the treatment of 20 patients with cervical dystonia; patients treated with BTX B showed dry mouth and greater hardness of habitual constipation in non-existence of onerous autonomic dysfunctions in each group of patients. (3)

Although BTX B affects neuromuscular cholinergic synapses, its clinical effects on autonomic cholinergic synapses are considerably stronger, as reflected by the adverse events reported. It is unclear whether this reflects either a rather higher fondness of BTX B, as compared to BTX A, for the sake of autonomic synapses, or the observation that doses of BTX B for production of neuromuscular effects in humans are several-fold higher than those of toxin A, such that at remedial neuromuscular doses, autonomic synapses are stimulated by BTX B. However, in our patients it seems conceivable that erectile dysfunction and dry mouth may represent, respectively, a local diffusion to autonomic targets and a systemic effect. Thus, accustomed its side effect profile, BTX B should be used carefully in patients with pre-existing autonomic dysfunction, other anticholinergic treatment, or conditions in which anticholinergics are contraindicated.

References:

1. Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: A double unthinking, randomized trial. Neurology 2005; 65: 765-767
2. Jankovich J. Treatment of cervical dystonia with botulinum toxin. Mov Disord 2004;19: S109-115
3. DresslerD, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperidrosis. Eur Neurol 2003; 49: 34-38

Written by Giuseppe Brisinda, MD, Federica Cadeddu, MD, and Giorgio Maria MD as part of Beyond the Theoretical on UroToday.com

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to:
www.urotoday.com

Copyright © 2008 - UroToday

Corresponding Originator
Giuseppe Brisinda
Department of Surgery
Catholic School of Medicine
University Hospital “Agostino Gemelli”
Largo Agostino Gemelli 8
00168 Rome (Italy)

Witness drug knowledge on Botox Cosmetic.

Late check out suggests that girls who were hyperactive when they were younger are more likely to have “serious” problems later in life.

The research by University College London and the University of Montreal, has revealed that one in ten girls have hyperactivity problems and this was linked to poor job prospects, abusive relationships and teenage pregnancy.

In a study of more than 881 Canadian girls up to the age of 21, the British and Canadian researchers found hyperactive girls were more likely to have poor school-leaving qualifications, become hooked on smoking and fall into mentally abusive relationships later in life.

The researchers say previous research on the lasting impact of childhood hyperactivity has focused on boys and they are more likely to be diagnosed and treated.

They say though hyperactivity is less common in girls, young girls with high levels of hyperactivity should also be targeted early in life to help them achieve at school.

Study leader, Dr. Nathalie Fontaine from University College, London, says there are currently very few interventions which target females.

The study assessed the girls yearly between the age of six and 12 and looked for signs of restlessness, jumping up and down, not keeping still, and being fidgety, and also assessed physical aggression such as fighting, bullying, kicking, biting or hitting.

The researchers found 1 in 10 showed high levels of hyperactive behaviour, while another 1 in 10 showed both high levels of hyperactive and physically aggressive behaviour.

They say those who were the most hyperactive or aggressive were more than twice as likely to be addicted to smoking, fall into mentally abusive relationships and four times more likely to do poorly at school.

Girls with both hyperactivity and physical aggression were found to report later problems of physical as well as psychological aggression towards their partner, along with early pregnancy and dependency on welfare.

However a quarter of the girls with hyperactivity had no problems in adulthood.

Dr. Fontaine says the findings were not unexpected and more research is needed to understand the factors that prevent or trigger the development of such problems.

Experts suspect that hyperactivity is diagnosed more commonly in boys because girls cause less trouble and they are often left to get on with things.

They also say schools often lack the skills or resources to deal with children with hyperactivity but the key is having someone who is sensitive to such needs.

The study is published in the latest issue of the Archives of General Psychiatry.